SLITRK6 and lung carcinoma: SLITRK6, FMO3, and LOC103021295, which do not have references for their expression in lung cancer, were decreased by 0.451, 0.277, 0.476, 0.486, 0.279, 0.432, 0.448, 0.186, and 0.257 FC value grouped in 3 sets (Table 2).